ReportAre patients with psoriasis undertreated? Results of National Psoriasis Foundation survey
Section snippets
Methods
The National Psoriasis Foundation conducts semiannual surveys to collect information about disease burden, treatment patterns, treatment satisfaction, and quality of life among patients with psoriasis and psoriatic arthritis. Participants were identified from a random sample of the National Psoriasis Foundation contact database, which lists more than 32,500 individuals. Through stratified sampling, approximately 400 surveys, balanced for age, sex, and disease severity (weighed to capture more
Results
There were a total of 1657 respondents who completed one of the 6 National Psoriasis Foundation surveys: 505 in 2003, 655 in 2004, and 497 in 2005. Of respondents, 28% (n = 459) reported their psoriasis as severe and 41% reported moderate psoriasis (n = 683).
Discussion
Many respondents with severe and moderate psoriasis were not being treated with systemic therapy as recommended in published reports. Nearly 40% of respondents, including those with severe and moderate disease, reported no current treatment at the time of their interview. In addition, less than 50% of respondents with severe psoriasis currently in treatment received traditional systemic or biologic therapy or phototherapy, which is recommended by the guidelines and consensus statements. The
References (20)
- et al.
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
J Investig Dermatol Symp Proc
(2004) Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
Dermatol Clin
(1996)- et al.
Determinants of quality of life in patients with psoriasis: a study from the US population
J Am Acad Dermatol
(2004) - et al.
Psoriasis
J Am Acad Dermatol
(2004) - et al.
Quality of life in patients with psoriasis: a systematic literature review
J Investig Dermatol Symp Proc
(2004) - et al.
Quantifying the harmful effect of psoriasis on health-related quality of life
J Am Acad Dermatol
(2002) - et al.
Psoriasis causes as much disability as other major medical diseases
J Am Acad Dermatol
(1999) Immunotherapy for psoriasis: from serendipity to selectivity
Lancet
(2002)- et al.
AAD consensus statement on psoriasis therapies
J Am Acad Dermatol
(2003) - et al.
Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey
J Am Acad Dermatol
(2005)
Cited by (0)
The National Psoriasis Foundation funded, designed, and conducted the surveys. Amgen and National Psoriasis Foundation collaborated for the analysis of treatment patterns in individuals with psoriasis. Strategic Healthcare Solutions, an independent consultant, was funded by Amgen for project design, statistical analysis, interpretation of data, drafting the article, and project management.
Disclosure: At the time of this work, Dr Horn was an employee of the National Psoriasis Foundation. The National Psoriasis Foundation receives unrestricted funding from Abbott Immunology, Amgen, Wyeth, Barrier Therapeutics, Biogen Idec, Centocor, Connetics Corporation, Daavlin, Galderma Laboratories, Genentech, National Biologic Corporation, Photomedex, UVBiotek, Valeant Pharmaceuticals, and Warner Chilcott. Dr Fox is a paid consultant to Amgen. Drs Patel, Chiou, and Dann are employees of Amgen. Dr Lebwohl has been a consultant and/or speaker for Amgen, Abbott, Astellas, Centocor, Genentech, Connetics, Pharmaderm, Novartis, Warner Chilcott, and Galderma Laboratories.
Presented in abstract and poster form at the Annual Meeting of the American Academy of Dermatology in Washington, DC, on February 3, 2007.